UBS lowered the firm’s price target on Repligen (RGEN) to $195 from $200 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen price target lowered to $170 from $180 at Evercore ISI
- Repligen: Solid Execution and Credible Growth Outlook, But Upside Limited at Current Valuation
- Repligen price target lowered to $180 from $190 at Wells Fargo
- Repligen price target lowered to $175 from $200 at Barclays
- Repligen Signals Confident Growth Path In 2026 Outlook